Table 3.
Baseline characteristics of patients receiving clinic-based methadone (MC), office-based methadone (MO) or buprenorphine (BO)
| Methadone | Buprenorphine | |||
|---|---|---|---|---|
| MC n=23 |
MO n=21 |
BO n=34 |
P-value | |
| Mean age in years (SD) | 41.0 (5.9)C | 42.8 (5.6)C | 35.6 (8.9)A,B | .001 |
| White, % (n) | 95.7 (22)B | 61.9 (13)A | 85.3 (29) | .01 |
| Male, % (n) | 65.2 (15) | 61.9 (13) | 85.3 (29) | .10 |
| Never married, % (n) | 39.1 (9) | 38.1 (8) | 58.8 (20) | .21 |
| High school degree, % (n) | 87.0 (20) | 85.7 (18) | 88.2 (30) | .96 |
| Fully Employed, % (n) | 78.3 (18) | 57.1 (12) | 52.9 (18) | .14 |
| Lifetime IVDU, % (n) | 87.0 (20)C | 57.1 (12) | 29.4 (10)A | <.001 |
| Known HIV+, % (n) | 4.3 (1)B | 28.6 (6)A,C | 2.9 (1)B | .005 |
| Prior Detoxification, % (n) | 100 (23) | 81.0 (17) | 76.5 (26) | .047 |
| Prior Opioid Agonist Treatment, % (n) | 52% (12) | 67% (14) | 41% (14) | .18 |
| Mean Years Regular Opioid Use (SD) | 15.2 (9.3)C | 12.0 (5.2) | 7.7 (6.4)A | .001 |
| Mean Monthly Income (legal) in 2006 dollars (SD) | 1,192 (1167) C | 1,375 (1176) C | 2,537 (2443) A, B | .02 |
| Mean days worked in previous month (SD) | 13.8 (10.2) | 18.0 (11.2) | 20.2 (8.2) | .07 |
A
Denotes a statistically significant difference from the MC group in post hoc testing
B
Denotes a statistically significant difference from the MO group in post hoc testing
C
Denotes a statistically significant difference from the BO group in post hoc testing
D
Includes periods of treatment with methadone or buprenorphine
IVDU: intravenous drug use
HIV+: known positive for the human immunodeficiency virus